# Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years

> **NCT00563953** · PHASE2 · COMPLETED · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 50 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Liposomal pegylated doxorubicine

## Key facts

- **NCT ID:** NCT00563953
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2011-02
- **Final completion:** 2016-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00563953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00563953, "Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00563953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*